You are here

Clinical Trial for Novel Stem Cell Stroke Therapy Advances to Phase 2 Stage

The product, SB623, is being delivered to the damaged region of the brains of people who have suffered an ischemic stroke, which results from an obstruction within a blood vessel supplying blood to the brain. Ischemic strokes account for 87 percent of all stroke cases.

SB623 consists of cells derived from genetically engineered bone marrow stromal (connective tissue) cells obtained from healthy adult donors. The therapy is administered adjacent to the area damaged by stroke and functions by producing proteins that aid the regenerative process. SB623 previously was shown to be safe and effective when tested in rodents suffering from chronic stroke.

The trial, which began in May 2012, is being conducted at Stanford University, the University of Pittsburgh and Northwestern University. To date, 12 patients of a planned total of 18, have received the injections with no safety concerns attributed to the product.

Dr. Ernest Yankee, SanBio's executive vice President of development, said, "We anticipate completing the enrollment of the third and final dose cohort early in the year and reporting the results shortly thereafter."

Learn more:
SanBio